Monter Cancer Center

Lake Success, New York 11067

0 studies enrolling now · 25 studies all time

What they study most

AML, Acute GVH Disease, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Breast Cancer, Carcinoma, Squamous Cell of Head and Neck, Chemotherapy-induced Peripheral Neuropathy, Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer

Studies at this site

• Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer — Completed
• Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia — Running, not enrolling
• Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) — Running, not enrolling
• A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer — Completed
• Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML — Completed
• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer — Stopped early
• A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer — Completed
• An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) — Completed
• A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer — Completed
• A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma — Completed
• Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) — Stopped early
• Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma — Completed
• Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients — Stopped early
• A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Completed
• Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck — Completed
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer — Completed
• A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia — Completed
• L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL — Stopped early
• MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease — Withdrawn before enrolling
• Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL — Stopped early
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer — Completed
• A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer — Completed
• Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer — Stopped early
• Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) — Completed
• Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML — Completed